secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001006837-25-000005
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MediBeacon's Transdermal GFR Monitor and Sensor approved by China NMPA; Lumitrace under review
--------------------------------------------------------------------------------

- China NMPA approved MediBeacon TGFR Monitor and Sensor for kidney function assessment; Lumitrace injection still under review, target approval late 2025.
- FDA approved the TGFR system on Jan 17, 2025; MediBeacon developing next-gen TGFR with updated software.
- Published studies: eGFR misclassified 35% of CKD patients; transdermal GFR showed r²=0.90 correlation with plasma mGFR across skin types.
- MediBeacon CEO highlighted partnership with Huadong Medicine for China rollout of the TGFR system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000005/0001006837-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000005/hchc-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001006837-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer